ELEV elevationoncology.com Final Profit

Corporate emblem and logo of Elevation Oncology, Inc. (ELEV)

Elevation Oncology is recruiting leading biologists to develop breakthrough therapies. Analyzing the company's total financial performance on GURU.Markets, we see how scientific potential influences quotes, where -0.05 serves as the final level mark. The model relies on external manufacturing outsourcing, which minimizes costs. Its pre-commercial status allows the company to focus on clinical data while avoiding price wars.

ELEV (Elevation Oncology) Net Profit history from 07/04/2022 to 08/02/2025

Analytical breakdowns and data insights for company Elevation Oncology, Inc. (ELEV)

- stock value and consensus price forecast:
Market Price elevationoncology.com|ELEV - Price Target Chart
- market capitalization data:
Market Value Elevation Oncology, Inc.|ELEV - Real Price to Acquire Entire Company
- business book valuation details:
Accounting Value of a Share Elevation Oncology|ELEV - Book Capitalization|Market Cap to Net Assets Ratio elevationoncology.com|ELEV - Cumulative Company Assets
- debt and solvency information:
Total Debt to Capital Elevation Oncology|ELEV - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital Elevation Oncology Inc.|ELEV - Company Aggregate Debts|Debts to Book Value Elevation Oncology, Inc.|ELEV - Company Long-Term Debts|Short-Term Debt Elevation Oncology|Quick Liquidity elevationoncology.com
- net income and valuation multiples indicators:
ELEV - Net Profit
Fundamental valuation:ELEV elevationoncology.com
Manufactured product of elevationoncology.com

The specific nature of Elevation Oncology (ELEV) targeted drug development, coupled with the risk of secondary offerings, renders traditional reporting lagging; consequently, the real-time market consensus more accurately reflects profit capitalization. While analyzing the company's net financial profit allows an investor to see the business value trend, the high volatility of binary trial outcomes necessitates portfolio diversification to protect against sharp trend corrections.

Direct competitors

Company Net Income BeiGene Oncology (ONC)|Company Net Income Halozyme Therapeutics|RVMD: Final Profit|Net Income AAPG (Ascentage Pharma)|CGON (CG Oncology Inc) - Final Profit|Net Profit URGN (UroGen)|BCAX - Net Income|PSNL: Net Income|ERAS - Net Profit|Delcath Systems (DCTH) - Company Net Income|Y-mAbs Therapeutics Inc - Final Profit|AURA (Aura Bio) - Net Profit|Company Net Income Candel CADL|Net Profit ARAY|SLS - Company Net Income|Company Net Income Actuate Therapeutics ACTU|Citius Oncology Inc. - Company Net Income|TuHURA - Net Profit|Company Net Income Protara Tx|FATE (Fate Therapeutics, Inc.) - Net Income|WHWK (Aadi Bioscience) - Company Net Income|TCRX (TScan Therapeutics Inc) - Net Profit|Net Profit Champions Oncology Corp|Net Income XBIT (XBiotech Inc.)|Profit After Payment of Taxes CVM|Net Profit OSTX (OS Therapies Incorporated)|Net Financial Result Radiopharm Theranostics Ltd (RADX)|ARTV - Company Net Income|Company Net Income Adlai Nortye Ltd.|Veru Pharma (VERU) - Company Net Income|Company Profit TPST|Net Income XLO|RENB: Final Profit|Company Net Income Mural Oncology plc (MURA)|KAPA - Company Net Income|Company Net Income OnKure Therapeutics OKUR|GDTC: Company Profit|Curis Corp - Net Profit|Apollomics, Inc. (APLM) - Net Income|Tharimmune (THAR) - Company Net Income|Company Net Income Advanced Biomed (ADVB)|Company Net Income Genprex, Inc|Company Net Income CLDI|Company Net Income Sunshine Biopharma (SBFM)|XBIO - Company Net Income|Net Profit SLRX (Salarius Pharmaceuticals, Inc.)|Annual Net Income Purple Biotech Ltd|AONC: Net Income|Company Net Income BeiGene Ltd|CKPT: Net Profit|Company Net Income iCAD (ICAD)|Company Net Income Ikena Oncology Inc.|Company Net Income NTBL|Net Profit VIRX|MOR - Company Net Income|NAYA Biosciences - Net Income|ascentage.com - Company Net Income